DOCSLIB.ORG

PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008 PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS o REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 de Agosto de 2008 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Luís Inácio Lula da Silva MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Miguel João Jorge Filho INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE PARANÁ Jorge de Paula Costa Ávila Chefe: Renee Fernando Senger Pernambuco Rua Marechal Deodoro, 344, 16º andar Universitária Federal de Pernambuco - UFPE VICE-PRESIDENTE Ademir Tardelli Edifício Atalaia, Centro, Curitiba - PR Av. Prof. Moraes Rego, 1235 – Campus Universitário CEP: 80010-909 Bairro - Engenho do Meio CHEFE DE GABINETE Telefone/Fax: (0XX-41) 3322-4411 Recife - PE - CEP: 50670-920 Josefina Sales de Oliveira RIO GRANDE DO SUL Tel/Fax:(0XX-81) 3453-8145 e 3271-1223 Chefe: Vera Lúcia de Seixas Grimberg Piauí DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA Rua Sete de Setembro, 515 – 5º andar - Centro Av. João XXIII, n° 865 Marco Antônio Lima Porto Alegre - RS - CEP: 90010-190 Espaço Cidadania Telefone/Fax.: (0XX-51) 3226-6909 e 3226-6422 Teresina - PI - CEP: 64049-010 PROCURADORIA GERAL SÃO PAULO Tel.:(0XX-86) 3235-9616/3218-1838 Mauro Sodré Maia Chefe: Maria dos Anjos Marques Buso Fax:(0XX-86) 3218-1838 DIRETORIA DE PATENTES Rua Tabapuã, 41 - 4º andar - Itaim-Bibi Rio Grande do Norte Carlos Pazos Rodrigues São Paulo - SP - CEP: 04533-010 SECRETÁRIA DO DESENVOLVIMENTO ECONÔMICO – DIRETORIA DE MARCAS Telefone/Fax: (0XX-11) 3071-3434 SEDEC BR 101 - Km 0 - 1 º andar - Lagoa Nova Terezinha de Jesus Guimarães Natal - RN - CEP: 59064-901 DIRETORIA DE TRANSFERÊNCIA DE TECNOLOGIA REPRESENTAÇÕES: Tel.: (0XX-84) 3232-1724 Breno Bello de Almeida Neves Acre Fax:(0XX-84) 3232-1745 DIRETORIA DE ADMINISTRAÇÃO E SERVIÇOS SECRETARIA DE ESTADO DE PLANEJAMENTO E Rondônia Julio Cesar Dutra De Oliveira DESENVOLVIMENTO SUSTENTÁVEL GERÊNCIA DE Rua Sete de Setembro, 830 – Centro Shopping Cidadão MARCAS E PATENTES REVISTA DA PROPRIEDADE INDUSTRIAL Porto Velho – RO – Cep: 78900-00 Rua Marechal Deodoro, 219 – 4º andar - Centro Tel.:(0XX-69) 3216-1031 e 3216-8636 Órgão Oficial do INSTITUTO NACIONAL DA Rio Branco - AC - CEP: 69.900-210 Fax: (0XX-69) 3216-1000 PROPRIEDADE INDUSTRIAL Tel./FAX : (0XX-68) 3229-4259 e 3229-6349 Roraima Lei nº 5648, de 11.12.70 art. 9º e decreto nº 68.104, de Alagoas JUNTA COMERCIAL DO ESTADO DE RORAIMA 22.01.71, art. 24 SECRETARIA DA INDUSTRIA E COM.SERVIÇO Av. Jaime Brasil, 157 - Centro Av. Da Paz, N.1108 - Centro Para adquirir RPI’s antigas o usuário deve entrar em Boa Vista - RR - CEP: 69.301-350 Jaranguá - Maceió - AL - CEP: 57022-005 contato com o SAP – Setor de Assinatura, localizado no Tel.: (0XX-95) 3224-9777, 3623-1220 e 3623-2437 Tel.: (0XX-82) 3315-721, 3315-1719 térreo da sede do INPI. Telefone: (0XX-21) 2139-3422 Fax.: (0XX-95) 623-2171 Amapá SANTA CATARINA SEDE DO INPI JUNTA COMERCIAL SECRETARIA DE DESENVOLVIMENTO ECONÔMICO E Av. FAB, 1610 – Centro - Macapá - AP - CEP: 68900-000 INTEGRAÇÃO AO MERCOSUL Praça Mauá nº 7 - Centro Tel.: (0XX-96) 3222-4867 Ramal 230 e 3222-4866 Av. Rio Branco, 387 / - Centro Rio de Janeiro - RJ - CEP: 20083-900 Fax: (0XX-96) 3222-3598 Florianópolis - SC - CEP: 88015-200 Tel.: PABX (0XX-21) 2139-3000 Amazonas Tel.: (0XX-48) 3223-5227/4827 Fax: INPI (0XX-21) 2263-2539 Rua Major Gabriel, n° 1870 – Praça 14 - Manaus – AM Fax.: (0XX-48) 3223-4827 PROC/DICONS CEP: 69020-060 Sergipe Tel.: (0XX-21) 2139-3731, 2139-3732 Tel.: (0XX-92) 2126-1235 e 2126-1200 Av. Tancredo Neves, n° 5.500 – Bairro América – Aracajú Fax: (0XX-21) 2253-9841 BAHIA – Sergipe – Cep: 49080-480 DIRMA - Diretoria de Marcas Rua Pedro R. Bandeira, 143 – 5º andar Tel/Fax – (79) 2106-7751 e 2106-7700 Diretoria... 10º andar Cidade Baixa – Salvador – Bahia Tocantins Tel.: (0XX-21) 2139-3758, 2139-3104, 2139-3214 CEP: 40015-080 SECRETARIA DE INDÚSTRIA, COMÉRCIO E TURISMO Fax: (0XX-21) 2139-3528 Tel.: (0XX-71)3326-9597 / 3242-5223 DO ESTADO DO TOCANTINS Central de atendimento: (0XX-21) 2139-3158 Fax.: (0XX-71) 242-5223 Praça dos Girassóis, snº - Marco Zero DIRPA - Diretoria de Patentes Espírito Santo Palmas - TO - CEP: 77003-900 Diretoria... 10º andar Rua Abigail do Amaral Carneiro, 191 Tel.: (0XX-63) 3218-2002, 218-2000 Tel.: (0XX-21) 2139-3592 e 2233-0785 Edifício Arábica – 3° andar – salas 312, 314 e 316 Fax: (0XX-63) 3218-2090 Fax: (0XX-21) 2139-3194 Enseada do Suá - Vitória - ES - CEP: 299055-907 DIRTEC - Diretoria de Transferência de Tecnologia Tel.: (0XX-27) 3235-7788 e 3315-9823 Esta Publicação é de responsabilidade da Coordenação Diretoria... 10º andar Goiás Geral Modernização e Informática Tel.: (0XX-21) 2139-3608, 2139-3648, 2139-3651 JUNTA COMERCIAL DO ESTADO DE GOIÁS Telefone: (21) 2139-3447 Fax: (0XX-21) 2253-0430 Rua 260 - Esquina 259 - Setor Universitário, Quadra 84/A DART - Diretoria de Articulação e Informação Tecnológica CEP:74610.310 Goiânia -GO Diretoria 10º andar Tel.: (0XX-62) 3202-2246 Tel.: (0XX-21) 2139-3354 Maranhão Fax: (0XX-21) 2233-5077 SUBDELEGACIA DE INDÚSTRIA E COMÉRCIO REPRESENTAÇÕES DO INPI NOS OUTROS ESTADOS Av. Carlos Cunha s/n°, Edifício Nagib Haickel – 1° andar DIVISÕES REGIONAIS Bairro Calhau - MA - CEP: 65065-180 Telefone/Fax: (0XX-98) 3218-9208 – 3218-9226 BRASÍLIA Mato Grosso Chefe: Antonio Carlos Pereira Coelho INMETRO/MT SAS - Quadra 2, Lote 1/A Rua Historiador Rubens de Mendonça, s/nº - CPA Brasília - DF - CEP: 70040-020 Cuiabá - MT - CEP: 78055-500 Tel. : (0XX-61) 224-1114 Tel.: (0XX-66) 3644-3095 Fax.: (0XX-61) 323-2520 Fax: (0XX-66) 3644-2902 CEARÁ Mato Grosso do Sul Chefe: Ary Gadelha de Alencar Araripe SECRETARIA DE TURISMO, INDÚSTRIA E COMÉRCIO Rua Doutor Mário Martins Coelho, nº 36 Junta Comercial/MS Aldeota - Fortaleza - CE - CEP: 60170-280 Rua Dr. Arthur Jorge, 1376 - Centro Tel.: (0XX-85) 3261-1372 e 3261-1695 Campo Grande - MS - CEP: 79010-210 Fax: (0XX-85) 3268-1495 Tel.: (0XX-67) 3316-4429 MINAS GERAIS Pará Chefe: Rafael Jardim Goulart de Andrade SEDE DA SECRETARIA DE ESTADO INDÚSTRIA, Avenida Amazonas nº 1.909 COMÉRCIO E MINERAÇÃO - SEICOM Santo Agostinho - Belo Horizonte - MG - CEP: 30180-002 Av. Presidente Vargas, 1020 Tel.: (0XX-31) 3291-5614 CEP: 66060-670 – Centro - Belém - PA Fax: (0XX-31) 3291-5449 Tel.: (0XX-91) 3217-5889 Fax: (0XX-91) 3217-5840 Paraíba Rua Feliciano Cisne n° 50 – Bairro Jaguaribe João Pessoa/PB - CEP: 58015-570 Tel./FAX(0XX-83) 3208-3922 - 3208-3923 e 3242- 2545/2729 Postos Avançados RPI 1964 de 26/08/2008 POSTOS AVANÇADOS – RIO DE JANEIRO POSTO AVANÇADO SANTARÉM / PA POSTOS AVANÇADOS – EM MINAS GERAIS CABO FRIO SANTARÉM JUIZ DE FORA ACIACF SEFA – Secretaria Estadual da Fazenda UNIVERSIDADE FEDERAL DE JUIZ DE FORA Rua Bento José Ribeiro, 18, 3º andar Av. Mendonça Furtado, 2797 – Bairro Fátima CRITT – CENTRO REGIONAL DE INOVAÇÃO E CEP: 28905-090 Santarém - Pará TRANSFERÊNCIA DE TECNOLOGIA Tel.: (0XX-24)2647-6333 CEP.: 68005-020 CAMPUS UNIVERSITÁRIO Tel.: (0XX-91) 523-2632 SÃO PEDRO CAMPOS CEP.: 36036-330 ACIC Tel.: (0XX-32)3229-3435 e 3229-3477 Praça São Salvador,41 , 16º andar Fax: (0XX-32)3229-3479 CEP: 28010-000 POSTO AVANÇADO SALVADOR / BA Tel.: (0XX-22) 2723-5174 PATROCÍNIO ACIP – ASSOCIAÇÃO COMERCIAL INDUSTRIAL DE NOVA FRIBURGO SALVADOR PATROCÍNIO ACINF SAC-EMPRESARIAL Rua Joaquim Carlos dos Santos, nº 141 – Cidade Jardim Av. Alberto Braune, nº111 , Térreo Av. Otávio Mangabeira, n° 6929 – Multishop Boca do Rio – CEP.: 38740-000 CEP:28613-001 Bairro Boda do Rio Tel.: (0XX-34) 3831-5500 Tel.: (0XX-22) 2522-1145 e 2522-8452 CEP.:41715-000 Tel.:(0XX-71) 281-4148 PETRÓPOLIS ASSOCIAÇÃO COMERCIAL EMPRESARIAL DE POSTO AVANÇADO RIO VERDE / GO PETRÓPOLIS Rua Irmãos D’Angelo nº 48 – 7º andar CEP: 25685-330 RIO VERDE Telefone/Fax (0XX-24) 237-1101 JCIRV Rua Augusta Bastos, 479 – Centro VOLTA REDONDA CEP.: 75900-000 ACIAVR Tel.: (0XX-64)3621-1985 Rua Assis Chateaubriand, nº 18 – Aterrado Fax: (0XX-64) 3613-1569 Volta Redonda - CEP: 27295-210 Telefone: (0XX-24) 3346-5332 Fax: (0XX-24)3347-2999 POSTOS AVANÇADOS - SANTA CATARINA CHAPECÓ ASSOCIAÇÃO COMERCIAL E INDUSTRIAL DE CHAPECÓ Av. Getúlio Vargas, 1748 - Centro CEP: 89805-100 Tel.: (0XX-49) 7323-4100 Fax.: (0XX-49) 7323-1723 JOINVILLE ASSOCIAÇÃO COMERCIAL E INDUSTRIAL DE JOINVILLE Rua do Príncipe, 330,10º andar CEP: 89200-000 Tel.: (0XX-47) 461-3364 RIO DO SUL ASSOCIAÇÃO COMERCIAL E INDUSTRIAL Rua XV de Novembro, 73 – s/174 - Centro Caixa Postal: 174 - CEP: 89290-000 Tel./Fax: (0XX-47) 821-3857 XANXERÊ ASSOCIAÇÃO COMERCIAL E INDUSTRIAL Av. Brasil, 260 - 5º andar - Edifícil Tiradentes Caixa Postal: 241 - CEP: 89820-000 Tel./Fax: (0XX-49)433-0420 Índice Geral RPI 1964 de 26/08/2008 Comunicados 5 Ministério do Desenvolvimento, Indústria e Comércio Exterior - Presidência do INPI 7 DIRETORIA DE PATENTES Exame Formal Preliminar – Índice Remissivo por Depositante - Exame Formal Preliminar – Índice Numérico Remissivo - Exigências Decorrentes do Exame Formal Preliminar - Tabela de Códigos de Despachos e Códigos INID de Pedidos, Patentes (incluindo as de MI/DI expedidas na vigência da Lei 5772/71) e Certificados de Adição de Invenção 9 Tabela de Códigos de Despachos de Pedidos e Patentes (incluindo as de MI/DI expedidas na vigência da Lei 5772/71) - Período de Transição (Lei 5772/71) 15 Índice Numérico Remissivo de Pedidos, Patentes e Certificados de Adição de Invenção 17 Notificação - Fase Nacional - PCT e Publicação de Pedidos de Patente e de Certificado de Adição de Invenção 21 Despachos Relativos a Pedidos, Patentes (incluindo as de MI/DI expedidas na vigência de Lei
Load more

Recommended publications
  • Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016
    Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016 Workshop Co-Chairs Maitreyee Hazarika, MD, Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr. Hazarika is a Senior Medical Officer in the Melanoma and Sarcoma Team in the Division of Oncology Products 2 (DOP2) of the Office of Hematology and Oncology Products (OHOP) in the Center for Drug Evaluation and Research (CDER) of the United States Food and Drug Administration (FDA). As a regulatory reviewer, she has reviewed new molecular entities for marketing approvals in solid tumors and hematological malignancies, which have included immunotherapies, targeted kinase inhibitors, immunomodulators and folate analog metabolic inhibitors. She has presented FDA review findings as a speaker at oncology drug advisory committee meetings and has authored manuscripts presenting summaries on FDA drug approvals. In addition to the regulatory experience at FDA, she has experience in global clinical drug development while an Associate Medical Director, Clinical Development at Celgene International and also provided consulting services as a subject matter expert in oncology and on regulatory and clinical aspects of pharmaceutical drug development while a Principal Consultant at Parexel Consulting. Dr. Hazarika received her MBBS and MD degrees in India and completed her internship and residency in Internal Medicine and fellowship in Medical Oncology and Hematology at the New York University School of Medicine. As a fellow, she co-authored a book chapter while active in clinical research in ovarian cancer. Marc Theoret, MD, Lead Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr.
    [Show full text]
  • Ste28.Pdf(469KB)
    Shiri Breznitz PhD Candidate, Dept. of Geography, University of Cambridge Email - [email protected] Research: My main focus is regional economic development. I am particularly interested in university-industry relationships and their influence on local economies. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz 28 Science, Technology and the Economy Program (STE) Working Papers Series STE-WP - 28 - 2005 From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz Department of Geography University of Cambridge STE – WP 28 May 2005 This is a report on a research project conducted as part of the activities of the Science Technology and the Economy Program, (STE), at the Samuel Neaman Institute for Advanced Studies in Science and Technology. This research was carried out as part of a larger project on the Role of the University in Regional Economic Development. The author is grateful to the MIT Industrial Performance Center (IPC), the Cambridge Political Economy Society Trust, and the STE program at the Samuel Neaman Institute, for their generous support of this research. This paper presents the author’s own view and not that of the Samuel Neaman Institute for Advanced Studies in Science and Technology or any members of its staff. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Abstract In 2001 Ernst & Young ranked the state of Connecticut seventh in the nation with respect to the number of biotech firms operating within its borders relative to its population (Ernst & Young, 2001).
    [Show full text]
  • Fiscal Year 2006/2007 Office of Research University of South Florida
    REPORT OF RESEARCH ACTIVITIES Fiscal Year 2006/2007 Office of Research University of South Florida December 2007 Office of Research University of South Florida 30338 USF Holly Drive Tampa, Florida 33620-3033 Phone: 813-974-5570 Fax: 813-974-3348 Email: [email protected] This document is also available on the USF Office of Research Web site at www.research.usf.edu FY06/07 TABLE OF CONTENTS SECTION 1 . 1-6 z Contact Information { Office of Research { Research Technologies { Research Resources { Sponsored Research { Research Integrity and Compliance { Comparative Medicine { Technology Development { Patents & Licensing { USF Research Foundation z Office of Research Web Site http://www.research.usf.edu z Research Activity Reports http://reports.research.usf.edu SECTION 2 . 7- 50 z Awards Data SECTION 3 . 51-186 z Project Awards: Detailed Funding SECTION 4 . 187-202 z Non-Project Awards: Detailed Funding SECTION 5 . 203-218 z Internal Awards Programs { Program Overview { Research Council Members { 2006 - 2007 Awards Table { Five-Year Summary { Detailed Funding SECTION 6 . 219-225 z Proposal Data UNIVERSITY OF SOUTH FLORIDA OFFICE OF RESEARCH REPORT OF RESEARCH ACTIVITIES FISCAL YEAR 2006/2007 SECTION 1 CONTACTS 1 2 Organizational and Contact Information as June 30, 2007 Office of Research Chang, Ph.D., Robert [email protected] (813) 974-5481 Vice President for Research Pope, Priscilla [email protected] (813) 974-2897 Associate Vice President Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Margin Stocks, Notice 97-22
    F e d e r a l R e s e r v e B a n k OF DALLAS ROBERT D. MCTEER, JR. _____ p r e s i d e n t DALLAS, TEXAS AND CHIEF EXECUTIVE OFFICER 75265-5906 March 10, 1997 Notice 97-22 TO: The Chief Executive Officer of each member bank and others concerned in the Eleventh Federal Reserve District SUBJECT Over-the-Counter (OTC) Margin Stocks DETAILS The Board of Governors of the Federal Reserve System has revised the list of over- the-counter (OTC) stocks that are subject to its margin regulations, effective February 10, 1997. Included with the list is a listing of foreign margin stocks that are subject to Regulation T. The foreign margin stocks listed are foreign equity securities eligible for margin treatment at broker- dealers. The Board publishes complete lists four times a year, and the Federal Register announces additions to and deletions from the lists. ATTACHMENTS Attached are the complete lists of OTC stocks and foreign margin stocks as of February 10, 1997. Please retain these lists, which supersede the complete lists published as of February 12, 1996. Announcements containing additions to and deletions from the lists will be provided quarterly. MORE INFORMATION For more information regarding marginable OTC stock requirements, please contact Eugene Coy at (214) 922-6201. For additional copies of this Bank's notice and the complete lists, please contact the Public Affairs Department at (214) 922-5254. Sincerely yours, yf f a * / ' . For additional copies, bankers and others are encouraged to use one of the following toll-free numbers in contacting the Federal Reserve Bank of Dallas: Dallas Office (800) 333 -4460; El Paso Branch Intrastate (800) 592-1631, Interstate (800) 351-1012; Houston Branch Intrastate (800) 392-4162, Interstate (800) 221-0363; San Antonio Branch Intrastate (800) 292-5810.
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]
  • Teligent Annual Report 2020
    Teligent Annual Report 2020 Form 10-K (NASDAQ:TLGT) Published: April 28th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-08568 TELIGENT, INC. (Formerly IGI Laboratories, Inc.) (Exact name of registrant as specified in its charter) Delaware 01-0355758 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 105 Lincoln Ave., Buena, New Jersey 08310 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (856) 697-1441 Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value Per Share TLGT The Nasdaq Stock Market Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Shire R&A 01 Cover
    Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc Annual review and summary financial statement 2001 Shire is proud of the part it plays in developing products which help people live their lives to the full. Shire, an international specialty pharmaceutical company, has a strategic focus on three therapeutic areas: central nervous system disorders, oncology and anti-infectives. It also has two platform technologies: advanced drug delivery and biologics. Our global sales and marketing infrastructure has an established product portfolio. Shire has its own marketing subsidiaries in the US, Canada, the UK and the Republic of Ireland, France, Germany, Italy and Spain, with plans to add Japan by 2004. We cover other pharmaceutical markets indirectly through distributors. Our interests in the Pacific Rim are managed through our regional office in Singapore. Shire has a risk-balanced R&D portfolio with clear focus on future product needs. Our global research and development expertise supported by in-licensing has, to date, successfully provided 20 marketed products, while the current pipeline of 24 projects includes 12 that are either in or post Phase II. To enhance the potential for future growth, Shire follows two approaches, firstly, to start projects in-house through research and advanced drug delivery and secondly to in-license projects and products on reasonable commercial terms, and then to develop and launch them. This broad approach strengthens Shire’s strategy and takes account of ongoing changes that are taking place in the industry. During the past seven years, we have completed six mergers and acquisitions and whereas we continue to evaluate M&A opportunities that offer a good strategic fit and add shareholder value, our priority is in-licensing more projects and products.
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 IGI Laboratories, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): 4) Proposed maximum aggregate value of transaction: 5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing: 1) Amount previously paid: 2) Form, Schedule or Registration Statement No: 3) Filing party: 4) Date Filed: IGI LABORATORIES, INC.
    [Show full text]
  • High Probability of Long-Term Survival in 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for AML in first Or Second CR
    Bone Marrow Transplantation (2011) 46, 385–392 & 2011 Macmillan Publishers Limited All rights reserved 0268-3369/11 www.nature.com/bmt ORIGINAL ARTICLE High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR NS Majhail1,2, R Bajorunaite3, HM Lazarus4, Z Wang3, JP Klein3, MJ Zhang3 and JD Rizzo3 1Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA; 2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; 3Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA and 4Division of Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH, USA We describe the long-term outcomes of autologous Introduction hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All After attainment of an initial remission, patients with AML patients were in continuous CR for X2 years after HCT. can receive consolidation therapy with either chemotherapy Patients were predominantly transplanted in CR1 (78%) or hematopoietic cell transplantation (HCT) based on and had good or intermediate cytogenetic risk disease various prognostic factors (for example, age, performance (74%). Median follow-up of survivors was 106 (range, status and cytogenetics). In general, patients with favorable 24–192) months. Overall survival at 10 years after HCT prognostic features receive consolidation chemotherapy was 94% (95% confidence intervals, 89–97%) and 80% only, whereas those with high-risk disease and an (67–91%) for patients receiving HCT in CR1 and CR2, acceptable risk of treatment-related morbidity and mortality respectively. The cumulative incidence of relapse at 10 are offered allogeneic HCT.
    [Show full text]
  • Orphan Drug Designations and Approvals List As of 12-02-2013 Governs January 1, 2014
    Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 Row Designation Generic Name Trade Name Orphan Designation Contact Company/Sponsor Num Date Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B‐cell Lymphoma of Mucosa‐ Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B‐cell Non‐Hodgkin's 1 bendamustine hydrochloride Treanda 11/26/2013 Lymphoma) Cephalon, Inc. Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear 2 Filgrastim Neupogen 11/20/2013 incident Amgen, Inc. adeno‐associated viral vector containing the human NADH Treatment of Leber Hereditary 3 Dehydrogenase 4 Gene n/a 11/20/2013 Optic Neuropathy Gen Sight Biologics Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and 4 emricasan n/a 11/20/2013 end stage liver disease Conatus Pharmaceuticals Inc. Page 1 of 262 Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 5‐((4‐bromo‐2‐ fluorophenyl)amino)‐4‐fluoro‐N‐(2‐ hydroxyethoxy)‐1‐methyl‐1H‐ Treatment Stage IIB‐IV Novartis Pharmaceuticals 5 benzo[d]imidazole‐6‐carboxamide n/a 11/19/2013 melanoma. Corporation Treatment of Hepatitis Delta 6 Lonafarnib n/a 11/19/2013 Virus (HDV)infection Eiger Biopharmaceuticals, Inc. Treatment in Stage IIB‐IV melanoma positive for the Novartis Pharmaceuticalues 7 MEK162
    [Show full text]
  • New Medicines in Development for Cancer Pharmaceutical Research and Manufacturers of America (Phrma) Drugs Are Listed Alphabetically Within Disease Category
    Pharmacy Practice New Medicines in Development for Cancer Pharmaceutical Research and Manufacturers of America (PhRMA) Drugs are listed alphabetically within disease category. Note: Selected agents have been chosen based on Phase III and IV status. † 354 NEW WEAPONS ARE IN DEVELOPMENT ME D I C I N E S I N D E V E L O P M E N T F O R C A N C E R * FOR THE WAR ON CANCER Can we declare victory in the war on cancer? “Wars are never won just like that – they’re a series of battles and skirmishes,” says cancer re s e a rcher Dr. Derek Raghavan of the University of California at Los Angeles. “If this were World War II, this would be 1943. We ’ r e about three quarters of the way there . ” Pharmaceutical re s e a r ch, by developing formidable weapons against cancer, has played a key role in the p r o g r ess against this disease. And a new survey found 354 additional medicines in development for cancer. The medicines include 63 for breast cancer, which strikes one out of every 10 American women; 58 for skin cancer including melanoma, the most serious form of skin cancer, whose incidence has grown 4 percent a year since the 1970s; 58 for lung cancer, the leading cause of cancer death in the US; and 46 for colon cancer, the second leading cancer killer of both men and women. These medicines in development *Some medicines are listed in more than one category.
    [Show full text]